[EN] VASOPRESSIN RECEPTOR ANTAGONISTS AND PRODUCTS AND METHODS RELATED THERETO<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE LA VASOPRESSINE, PRODUITS ET PROCÉDÉS ASSOCIÉS
申请人:BLACKTHORN THERAPEUTICS INC
公开号:WO2019050988A1
公开(公告)日:2019-03-14
Compounds are provided that antagonize vasopressin receptors, particularly the V1a receptor products containing such compounds, as well as to methods of their use and synthesis. Such compounds have the structure of Formula (I), or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof: (I) wherein Q1, Q2, Q3, R2a, R2b, R3 and X are as defined herein.
Provided are: a heterocyclic amide compound represented by formula (1); and a herbicide containing the heterocyclic amide compound. In the formula, G represents a group represented by formula (G-1) or (G-2); each of W and W
1
independently represents an oxygen atom or the like; each of Z
1
and Z
a1
represents a phenyl group or the like; Z
2
represents an aromatic heterocycle; each of R
1
and R
2
independently represents a C
1
-C
6
alkyl group or the like; R
3
represents a hydrogen atom, a C
1
-C
6
alkyl group or the like; and each of R
4
, R
a4
, R
5
, R
a5
, R
6
, R
a6
and R
7
independently represents a hydrogen atom or the like.
[EN] HETEROARYL COMPOUNDS AS INHIBITORS OF PROGRAMMED NECROSIS PATHWAY, COMPOSITION AND METHOD USING THE SAME<br/>[FR] COMPOSÉS HÉTÉROARYLE EN TANT QU'INHIBITEURS DE LA VOIE DE NÉCROSE PROGRAMMÉE, COMPOSITION ET PROCÉDÉ FAISANT APPEL À CEUX-CI
申请人:ZHANG XIAOHU
公开号:WO2021138694A1
公开(公告)日:2021-07-08
The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to the programmed necrosis pathway.
[EN] QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS<br/>[FR] MODULATEURS ALLOSTÉRIQUES POSITIFS DU RÉCEPTEUR M1 DE TYPE QUINOLIZIDINONE
申请人:MERCK & CO INC
公开号:WO2009094279A1
公开(公告)日:2009-07-30
The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM
申请人:McKittrick A. Brian
公开号:US20080089858A1
公开(公告)日:2008-04-17
Disclosed are compounds of the formula:
and compounds of the formula:
wherein R
1
, R
2
, R
3
, R
4
, R
5
, u and v are as defined herein. Also disclosed are methods of treating pain (e.g., inflammatory pain, chronic pain, and neuropathic pain), methods of treating diabetes, and methods of inhibiting the absorption of cholesterol using compounds of formula I or IIA.